WO2022252663A1 - 酒精和凉味剂的组合物在调节性功能、保护心脑血管系统、促进肝细胞再生、抗肿瘤、提高免疫及睡眠质量上的用途 - Google Patents

酒精和凉味剂的组合物在调节性功能、保护心脑血管系统、促进肝细胞再生、抗肿瘤、提高免疫及睡眠质量上的用途 Download PDF

Info

Publication number
WO2022252663A1
WO2022252663A1 PCT/CN2022/074407 CN2022074407W WO2022252663A1 WO 2022252663 A1 WO2022252663 A1 WO 2022252663A1 CN 2022074407 W CN2022074407 W CN 2022074407W WO 2022252663 A1 WO2022252663 A1 WO 2022252663A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
acid
alcohol
cooling agent
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2022/074407
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
张雪峰
马国霞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qinghai Spring Medicinal Resources Technology Co Ltd
Original Assignee
Qinghai Spring Medicinal Resources Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qinghai Spring Medicinal Resources Technology Co Ltd filed Critical Qinghai Spring Medicinal Resources Technology Co Ltd
Priority to EP22814712.0A priority Critical patent/EP4353263B1/en
Priority to JP2023575352A priority patent/JP2024523005A/ja
Priority to US18/565,673 priority patent/US20240252453A1/en
Publication of WO2022252663A1 publication Critical patent/WO2022252663A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention belongs to the fields of medicine, health care and food, and specifically relates to the use of the composition of alcohol and cooling agent in regulating sexual function, protecting cardiovascular and cerebrovascular systems, promoting liver cell regeneration, anti-tumor, improving immunity and sleep quality.
  • Progesterone increases libido in women, and dopamine increases libido and arousal.
  • the formula of the composition is: the cooling agent is prepared from menthyl acetate, L-menthyl lactate, and monomenthyl succinate in a weight ratio of 4:5:1, and the content is 0.05ppm; the organic acid is acetic acid, lactic acid, propane Acid, butyric acid and caproic acid are prepared according to the weight ratio of 14:15:1.5:1:1. After blending, the organic acid content is 150ppm; the alcohol base is beer with an alcohol content of 4.5% vol, and then blended with purified water. Composition 1 was made so that the final alcohol content of the composition was 1% vol.
  • the formula of the composition is: the cooling agent is prepared from menthyl acetate, L-menthyl lactate, and monomenthyl succinate in a weight ratio of 4:5:1, and the content is 5ppm; the organic acid is acetic acid, lactic acid, propionic acid , butyric acid and hexanoic acid are formed according to the weight ratio of 14:15:1.5:1:1. After deployment, the organic acid content is 500ppm, and the wine base is 15% vol. Diluted to 0.5% vol with pure water to obtain Composition 8.
  • the composition formula is: the cooling agent is monomenthyl succinate, mono-L-menthyl glutarate and N-ethyl-2-isopropyl-5-methyl-cyclohexanecarboxamide by weight 2:5:3 formulated with a content of 0.04ppm; organic acids are acetic acid, lactic acid, propionic acid, succinic acid, valeric acid and heptanoic acid in a weight ratio of 7:8:1:2:1:1 After blending, the organic acid content was 2000ppm, and the alcohol base was Maotai-flavored liquor with an alcohol content of 53% vol, so that the composition 9 was prepared.
  • the cooling agent is monomenthyl succinate, mono-L-menthyl glutarate and N-ethyl-2-isopropyl-5-methyl-cyclohexanecarboxamide by weight 2:5:3 formulated with a content of 0.04ppm
  • organic acids are acetic acid, lactic acid, propi
  • composition 12 The formula of the composition is as follows: the organic acids acetic acid, succinic acid, caproic acid, citric acid and malic acid are prepared in a weight ratio of 3:1:1:4:2. After deployment, the organic acid content is 2000ppm. Composition 12 was prepared as a Maotai-flavor liquor with an alcohol content of 53%vol.
  • the various indicators of the compositions prepared in the examples and comparative examples were evaluated for sexual function, cardiovascular and cerebrovascular system, promotion of liver cell regeneration, anti-tumor, improvement of immunity and sleep quality.
  • the specific method is as follows:
  • the serotonin (5-HT) level of the experimental group drinking the composition prepared in the examples increased significantly, and the compositions 10 and 13-16 with low acidity and no organic acid also had a small increase, but increased The percentage is not as good as compositions 1-7. And no alcohol and low alcohol content, as well as no cooling agent and low cooling agent serotonin (5-HT) levels before and after drinking basically no difference. It is proved that the composition of the present invention can increase the level of serotonin (5-HT) in women, thereby indicating that the composition can promote liver cell regeneration and improve immunity by increasing the level of 5-HT in women.
  • estradiol (E 2 ) in the experimental group drinking the compositions prepared in the examples increased, and the low acidity and organic acid-free compositions 10 and 13-16 also had a small increase, but The percentage increase is not as good as compositions 1-7.
  • the composition of the present invention can increase the level of estradiol (E 2 ) in women, thus indicating that the composition can regulate sexual function by increasing the level of E 2 in women.
  • the nitric oxide level of the experimental group drinking the composition prepared in the example increased significantly, while the low acidity and organic acid-free compositions 10 and 13-16 did not increase significantly.
  • the no- and low-alcohol, and no-coolant and low-coolant comparisons showed little or no increase in nitric oxide levels. It is proved that the composition of the present invention can effectively increase the level of nitric oxide in women, thus indicating that the composition can regulate sexual function and protect cardiovascular and cerebrovascular systems by increasing the level of nitric oxide in women.
  • composition sample before drinking after drinking increase/decrease% Composition 1 0.75 ⁇ 0.35 0.94 ⁇ 0.46 25.33 Composition 2 1.20 ⁇ 0.71 1.54 ⁇ 0.84 28.33 Composition 3 1.82 ⁇ 0.85 2.35 ⁇ 1.14 29.12 Composition 4 0.95 ⁇ 0.48 1.19 ⁇ 0.65 25.26 Composition 5 0.48 ⁇ 0.21 0.63 ⁇ 0.28 31.25 Composition 6 1.30 ⁇ 0.76 1.71 ⁇ 0.92 31.54 Composition 7 0.63 ⁇ 0.36 0.85 ⁇ 0.32 34.92 Composition 8 1.44 ⁇ 0.62 1.46 ⁇ 0.77 1.39 Composition 9 1.78 ⁇ 0.64 1.77 ⁇ 0.92 -0.56 Composition 10 0.85 ⁇ 0.42 0.98 ⁇ 0.55 15.29 Composition 11 1.64 ⁇ 0.71 1.66 ⁇ 0.90 1.22 Composition 12 1.58 ⁇ 0.64 1.57 ⁇ 0.92 -0.63 Composition 13 0.59 ⁇ 0.29 0.68 ⁇ 0.31 15.25
  • the composition of the present invention has the effects of improving sexual function, protecting the cardiovascular and cerebrovascular system, promoting liver cell regeneration, anti-tumor, improving immunity and sleep quality, and it is also found to be accompanied by increased and persistent saliva secretion.
  • the effects of the composition of the present invention on improving sexual function, protecting cardiovascular and cerebrovascular systems, promoting liver cell regeneration, anti-tumor, improving immunity and sleep quality may be regulated by activating parasympathetic nerve signal pathway. Therefore, by testing the expression of M3 receptors and the contents of PLC and IP3 in the signaling pathway, it can be reflected that the parasympathetic nerve signal channel is activated.
  • the test method is as follows:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Alcoholic Beverages (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/CN2022/074407 2021-06-02 2022-01-27 酒精和凉味剂的组合物在调节性功能、保护心脑血管系统、促进肝细胞再生、抗肿瘤、提高免疫及睡眠质量上的用途 Ceased WO2022252663A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP22814712.0A EP4353263B1 (en) 2021-06-02 2022-01-27 Composition of alcohol and cooling agent for regulating sexual functions, protecting cardiovascular and cerebrovascular systems, promoting regeneration of liver cells, and improving immunity and sleep quality
JP2023575352A JP2024523005A (ja) 2021-06-02 2022-01-27 性機能の調節、心血管系及び脳血管系の保護、肝細胞再生の促進、腫瘍の予防及び／又は処置、並びに免疫及び睡眠の質の改善における、アルコールと冷感剤との組成物の使用
US18/565,673 US20240252453A1 (en) 2021-06-02 2022-01-27 Use of composition of alcohol and cooling agent in regulating sexual functions, protecting cardiovascular and cerebrovascular systems, promoting regeneration of liver cells, preventing and/or treating tumors, and improving immunity and sleep quality

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110614624 2021-06-02
CN202110614624.2 2021-06-02

Publications (1)

Publication Number Publication Date
WO2022252663A1 true WO2022252663A1 (zh) 2022-12-08

Family

ID=80754836

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/074407 Ceased WO2022252663A1 (zh) 2021-06-02 2022-01-27 酒精和凉味剂的组合物在调节性功能、保护心脑血管系统、促进肝细胞再生、抗肿瘤、提高免疫及睡眠质量上的用途

Country Status (5)

Country Link
US (1) US20240252453A1 (https=)
EP (1) EP4353263B1 (https=)
JP (1) JP2024523005A (https=)
CN (1) CN114225038A (https=)
WO (1) WO2022252663A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114225038A (zh) * 2021-06-02 2022-03-25 青海春天药用资源科技股份有限公司 酒精和凉味剂组合物在调节性功能、护血管、肝细胞再生、抗肿瘤、提高免疫及睡眠的用途
CN115590967A (zh) * 2022-10-20 2023-01-13 青海春天药用资源科技股份有限公司（Cn） 酒精、凉味剂和有机酸的组合物在制备降血压及改善绝经期女性激素水平的组合物上的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109022223A (zh) * 2017-06-09 2018-12-18 宜宾凉露酒业有限公司 凉口型配制酒及其制备方法
CN109022188A (zh) * 2017-06-09 2018-12-18 宜宾凉露酒业有限公司 采用强化曲制备凉口型白酒的方法
CN114225038A (zh) * 2021-06-02 2022-03-25 青海春天药用资源科技股份有限公司 酒精和凉味剂组合物在调节性功能、护血管、肝细胞再生、抗肿瘤、提高免疫及睡眠的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2209490T3 (es) * 1998-10-13 2004-06-16 Pfizer Products Inc. Concentrado oral de sertralina.
JP4773070B2 (ja) * 2004-07-27 2011-09-14 株式会社ナカムラ酵素 米糠等発酵調合液の製造方法
JP2010239872A (ja) * 2009-04-01 2010-10-28 Sanei Gen Ffi Inc 食用酸を含有する製品中のメントールの苦味低減方法
JP6556455B2 (ja) * 2015-01-26 2019-08-07 サントリーホールディングス株式会社 果実酒
CN109248226A (zh) * 2018-11-22 2019-01-22 福泉星合养生发展有限公司 一种理疗保健油

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109022223A (zh) * 2017-06-09 2018-12-18 宜宾凉露酒业有限公司 凉口型配制酒及其制备方法
CN109022188A (zh) * 2017-06-09 2018-12-18 宜宾凉露酒业有限公司 采用强化曲制备凉口型白酒的方法
CN114225038A (zh) * 2021-06-02 2022-03-25 青海春天药用资源科技股份有限公司 酒精和凉味剂组合物在调节性功能、护血管、肝细胞再生、抗肿瘤、提高免疫及睡眠的用途

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"High Potential Hyperthermia", 31 January 2015, PEOPLE'S MILITARY MEDICAL PRESS, CN, ISBN: 978-7-5091-8180-5, article ZHU, PING ET AL.: "Effect of Regulating and Balancing Autonomic Nerve", pages: 36 - 38, XP009541671 *
"Physiology of Human Information Control System: Modern Chinese Medicine Physiology and Pharmacology (Part I)", 31 October 1997, INNER MONGOLIA PEOPLE'S PUBLISHING HOUSE, CN, ISBN: 7-204-03730-8, article GAO, LIANG ET AL.: "Control Function of Control Pathway of Parasympathetic Signaling System In Vivo", pages: 370 - 373, XP009542828 *
CHEN QIAN; LI QIANG: "Advances in research on the neuroendocrine compartment of the liver", WORLD CHINESE JOURNAL OF DIGESTOLOGY, SHIJE WEI-CHANGBINGXUE ZAZHISHE , TAIYUAN, CN, vol. 14, no. 30, 28 October 2006 (2006-10-28), CN , pages 2954 - 2957, XP009541648, ISSN: 1009-3079 *
LUBOBO‐CLAUDE KAZADI; JANINE FLETCHER; PAUL A. BARROW: "Gastric cooling and menthol cause an increase in cardiac parasympathetic efferent activity in healthy adult human volunteers", EXPERIMENTAL PHYSIOLOGY, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 103, no. 10, 19 August 2018 (2018-08-19), GB , pages 1302 - 1308, XP071897717, ISSN: 0958-0670, DOI: 10.1113/EP087058 *
See also references of EP4353263A4 *
YANG, MING: "Exploration and Research on Healthy Liquor——Using "Chemical Enhancement Technology" to Realize Liquor Properties and Promote Sanitation, Experimental Research on the Effects on Human Immune Indexes, Serotonin, Sex Hormone Levels and Sleep", CHINA FOOD, no. 11, 1 June 2021 (2021-06-01), pages 88 - 93, XP009541670, ISSN: 1000-1085 *

Also Published As

Publication number Publication date
US20240252453A1 (en) 2024-08-01
JP2024523005A (ja) 2024-06-25
EP4353263A4 (en) 2024-11-06
EP4353263A1 (en) 2024-04-17
EP4353263B1 (en) 2026-05-06
CN114225038A (zh) 2022-03-25

Similar Documents

Publication Publication Date Title
Ni et al. Astragaloside IV improves neurobehavior and promotes hippocampal neurogenesis in MCAO rats though BDNF-TrkB signaling pathway
US9060999B2 (en) Ellagitannins rich extracts composition
WO2022252663A1 (zh) 酒精和凉味剂的组合物在调节性功能、保护心脑血管系统、促进肝细胞再生、抗肿瘤、提高免疫及睡眠质量上的用途
JP6573293B2 (ja) 炎症性疾患の予防または治療用ペプチド及びこの用途
CN106666746B (zh) 具有调节神经递质平衡功能的芦笋组合物及其制备方法、芦笋组合物粉剂
KR20200038408A (ko) IF1 (ATPase inhibitory factor 1)을 유효성분으로 함유하는 근감소증의 예방 또는 치료용 약학 조성물
CN107320674B (zh) 一种改善认知、延缓痴呆病情进展的中药组合物及其应用
JP2011241209A (ja) ガングリオシド又はその誘導体を有効成分とするｂｄｎｆ産生促進剤並びにそれを含有する医薬品、飲食品及び飼料
CN117679522A (zh) 用于防治神经系统病变的药物组合物及其应用
CN108473536B (zh) 用于预防或治疗炎症性疾病的肽及其用途
WO2012056475A2 (en) Composition for improving sexual health
EP1569635A1 (en) Use of carnitines for the prevention and/or treatment of disorders caused by the andropause
CN117813103A (zh) 包含功能增强干细胞的用于预防或治疗特应性皮炎的组合物
JP4305806B2 (ja) 抗ストレス剤
JP2009114080A (ja) アトピー性皮膚炎治療組成物
CN115590967A (zh) 酒精、凉味剂和有机酸的组合物在制备降血压及改善绝经期女性激素水平的组合物上的用途
RU2839802C1 (ru) Способ реабилитации больных с синдромом хронической усталости после перенесенной коронавирусной инфекции на основе пептидных биорегуляторов с помощью спрея сублингвального введения
CN113181342B (zh) 一种治疗抑郁的凝结芽孢杆菌制剂
WO2019172737A1 (ru) Способ лечения энцефалопатии
RU2242235C1 (ru) Наномолекулярное селенотерпенопротеиновое средство и способ лечения больных с зависимостью от психоактивных веществ
TW202600149A (zh) 勃起障礙改善劑、男性更年期障礙改善劑
JP6694216B2 (ja) グレリンを有効成分として含有するレット症候群（ｒｔｔ）の予防・治療剤
US6476073B1 (en) Method of treating a hangover by enhancing the effectiveness of the human immune system
HK40020447B (zh) 包含芝麻酚和肽的缀合物作为活性成分的缓解宿醉的组合物
RU2610438C2 (ru) Способ лечения патологического синдрома и лекарственное средство центрального и периферического действия для лечения патологического синдрома

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22814712

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 18565673

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2023575352

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2022814712

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2022814712

Country of ref document: EP

Effective date: 20231213

NENP Non-entry into the national phase

Ref country code: DE